X
Access Company Profiles

Get business overview, business operations details specific to this market, products and services, latest developments and more...

Business Email

Select Companies

 

Neuropathic Pain Companies

This report lists the top Neuropathic Pain companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Neuropathic Pain industry.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Developmental Anomalities Research Neuropathic Pain Market Companies

Neuropathic Pain Top Companies

  1. Grünenthal

  2. Mallinckrodt Pharmaceuticals

  3. Pfizer, Inc.

  4. Novartis AG

  5. Teva Pharmaceutical Industries Ltd.

*Disclaimer: Top companies sorted in no particular order

Neuropathic Pain Market Major Players

Neuropathic Pain Market Concentration

Neuropathic Pain Market Concentration

Neuropathic Pain Company List

                              • Grünenthal

                              • Mallinckrodt Pharmaceuticals

                              • GlaxoSmithKline Plc

                              • Pfizer, Inc.

                              • Cipla, Inc. (InvaGen Pharma)

                              • Glenmark

                              • Centaur Pharmaceuticals

                              • Sun Pharmaceutical Industries Ltd.

                              • Teva Pharmaceutical Industries Ltd.

                              • Dr. Reddy's Laboratories Ltd.

                              • Lupin Ltd.

                              • Laurus Labs

                              • Lannett Co Inc


                          Specific to Neuropathic Pain Market
                          Need More Details On Market Players And Competitors?
                          Download Sample

                          Neuropathic Pain Market Report Snapshots

                          Neuropathic Pain Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)